|Day Low/High||2.82 / 2.94|
|52 Wk Low/High||1.35 / 11.11|
Company reaffirms NDA submission by year end 2017
Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity
Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data
Evoke Pharma (EVOK) reported a smaller-than-anticipated loss for the 2016 second quarter after Monday's closing bell.
Here's a technical look at how to trade five stocks trading for less than $10 a share.
Evoke Pharma (EVOK) shares continue to fall today after the company's diabetic gastroparesis trials missed topline results on Monday.
Evoke Pharma’s (EVOK) diabetic gastroparesis drug missed its primary endpoint in phase 3 topline results.
205 subjects complete the study
Further Safety of EVK-001 Demonstrated with TQT Results